Biochemical Engineering Special Interest Group
biological engineering professionals
26 January 2016

Albumedix buys Eleven's half-life boosting albumin assets

Eleven Biotherapeutics, Inc. and Albumedix today announced that Eleven and Albumedix have entered into an agreement that will see Albumedix acquire Eleven's proprietary Supermin® albumin variant assets. Eleven's albumin technology will complement Albumedix's proprietary drug delivery platform, Veltis®, extending the array of technologies available for use by clients developing drugs with longer duration of systemic exposure. Source: Eleven press release 26/1/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).